

DAFTAR PUSTAKA

1. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia - An Overview. Vol. 77, JAMA Psychiatry. American Medical Association; 2020. hlm. 201–10.
2. Kementrian Kesehatan RI. Laporan Riskesdas 2018 Nasional. Jakarta; 2018.
3. Wijayanti A, Andan Puspitosari W, Studi Pendidikan dokter P, Kedokteran dan Ilmu Kesehatan F, Muhammadiyah Yogyakarta U, Kejiwaan B. Hubungan Onset Usia dengan Kualitas Hidup Penderita Skizofrenia di Wilayah Kerja Puskesmas Kasihan II Bantul Yogyakarta The Correlation Age of Onset with Quality of Life Schizophrenia Patient in the Work Area Kasihan Primary Health Care II Bantul Yogyakarta. Mutiara Medika. Januari 2014;14(1):47–53.
4. Zahnia S, Wulan Sumekar D. Kajian Epidemiologis Skizofrenia. Medical Journal Of Lampung University. 2016;5(4).
5. Afni N, Andri M, Sudarmono. Faktor Risiko Kejadian Skizofrenia Di Rumah Sakit Madani Palu. Jurnal Kolaboratif Sains. Oktober 2018;1(1).
6. Aryani F, Sari O. Gambaran Pola Penggunaan Antipsikotik Pada Pasien Skizofrenia Di Ruang Rawat Inap Rumah Sakit Jiwa. Jurnal Manajemen dan Pelayanan Farmasi. Maret 2016;6(1).
7. Kementrian Kesehatan RI. Keputusan Menteri Kesehatan RI NOMOR HK.02.02/MENKES/73/2015 PEDOMAN NASIONAL PELAYANAN KEDOKTERAN JIWA. Jakarta; 2015.
8. Azmi AN, Desrini S. A cross sectional study of trihexyphenidyl utilization on patient receiving antipsychotic therapy. Jurnal Kedokteran dan Kesehatan Indonesia. 17 Juni 2016;7(3):102–8.
9. D'Souza RS, Hooten WM. Extrapyramidal Symptoms [Internet]. StatPearls. 2022 [dikutip 1 Desember 2022]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK534115/>
10. Rahaya A, Cahaya N. Studi Retrospektif Penggunaan Triheksifenidil Pada Pasien Skizofrenia Rawat Inap Yang Mendapat Terapi Antipsikotik Di Rumah Sakit Jiwa Sambang Lihum. GALENIKA JOURNAL OF PHARMACY . Oktober 2016;2(2):124–31.
11. Jilani TN, Sabir S, Sharma S. Trihexyphenidyl [Internet]. StatPearls. 2021 [dikutip 1 Desember 2022]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK519488/?report=classic>
12. Sheikh WA, Sheikh WA. Prophylactic Use of Trihexyphenidyl (Artane) in Schizophrenia and Psychosis: A Critical Review of Literature to Guide for

Evidence Based Practice in Zambia. *Med J Zambia*. Agustus 2019;46(2):133–9.

13. Maharani RP, Susanti R. Profil Anticholinergic Burden Pada Psikogeriatri Penderita Skizofrenia Di Rumah Sakit Jiwa Sungai Bangkong Pontianak. *Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN*. Juni 2019;4(1).
14. Vivi Swayami IGA. Aspek Biologi Triheksifenidil di Bidang Psikiatri. *Medicina (B Aires)*. Mei 2014;45(2).
15. Musdalifah W, Susanti R. Evaluasi Penggunaan Obat Triheksifenidil Sebagai Terapi Adjuvan Pada Pasien Skizofrenia Di Instalasi Rawat Inap Rumah Sakit Jiwa Daerah Sungai Bangkong Pontianak. *Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN*. 2019;4(1).
16. Dinas Kesehatan Sumatera Barat. Profil Kesehatan Provinsi Sumatera Barat 2020. Padang; 2020.
17. Sadock BJ, Sadock VA. *Buku Ajar Psikiatri Klinis Kaplan*. 2nd ed. Jakarta: EGC; 2010.
18. Elvira. *Buku Ajar Psikiatri*. 3rd ed. Jakarta: FKUI; 2017.
19. Maslim R. *Buku Saku Diagnosis Gangguan Jiwa : Rujukan Ringkas dari PPDGJ III*. 2nd ed. Vol. III. Jakarta: Ilmu Kedokteran Jiwa Fakultas Kedokteran Unika Atma Jaya; 2013.
20. Kartikadewi A, Suprihatini. *Buku Ajar Sistem Neurobehaviour (Psikiatri)*. Semarang: Fakultas Kedokteran Universitas Muhammadiyah Malang; 2015.
21. Gejman P v., Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. *Psychiatric Clinics of North America*. Maret 2010;33(1):35–66.
22. Lim C, Chong SA, Keefe RS. Psychosocial Factors in the Neurobiology of Schizophrenia: A Selective Review. *Ann Acad Med Singap*. Mei 2009;38(5):402–6.
23. Patel K, Cherian J, Gohil K, Atkinson D. Schizophrenia: Overview and Treatment Options. *P&T*. September 2014;39(9):638–45.
24. Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: Dopamine, serotonin, and glutamate. *CNS Spectr*. 1 Juni 2018;23(3):187–91.
25. American Psychiatric Association. *Diagnostic And Statical Manual Of DSM-5*. 5th ed. London: American Psychiatric Publishing; 2013.
26. Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. *Handb Exp Pharmacol*. 2012;213:11–37.

27. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Vol. 388, The Lancet. Lancet Publishing Group; 2016. hlm. 86–97.
28. Amanda N, Zukna M, Lisiswanti R. Pasien dengan Halusinasi dan Waham Bizarre. *Jurnal Medula Unila*. 2017;7(1).
29. Fariba KA, Fawzy F. Delusions [Internet]. StatPearls Publishing. 2021 [dikutip 3 Agustus 2022]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK563175/>
30. Arciniegas DB. Psychosis. *Continuum: Lifelong Learning in Neurology* [Internet]. Juni 2015;21(3). Tersedia pada: www.ContinuumJournal.com
31. Hany M, Rehman B, Azhar Y, Chapman J. Schizophrenia [Internet]. StatPearls Publishing. 2022 [dikutip 3 Agustus 2022]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK539864/>
32. Dorofeikova M, Neznanov N, Petrova N. Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. *Psychiatry Res*. 1 April 2018;262:542–8.
33. Chokhawala K, Stevens L. Antipsychotic Medications [Internet]. StatPearls Publishing. 2021 [dikutip 18 Oktober 2021]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK519503/>
34. Katzung BG. *Basic & Clinical Pharmacology* [Internet]. 12th ed. Katzung BG, Masters SB, Trevor AJ, editor. New York: Mc Graw - Hill; 2012. Tersedia pada: <http://www.usdoj.gov/dea/pubs/scheduling.html>
35. Kusuma D, Dewi AK, Hermanto B. Pengaruh Pemberian Triheksifenidil Dosis Bertingkat Per Oral terhadap Diameter Lumen Tubulus Ginjal Mus Musculus. *eJournal Kedokteran Indonesia*. Desember 2017;5(3).
36. Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Vol. 30, *Trends in Pharmacological Sciences*. 2009. hlm. 148–55.
37. Stahl SM. *Stahl's Essential Psychopharmacology : Neuroscientific Basis and Practical Applications*. 5th ed. Cambridge: Cambridge University Press; 2021.
38. Naja WJ, Halaby A. Anticholinergic Use and Misuse in Psychiatry: A Comprehensive and Critical Review. *J Alcohol Drug Depend*. 2017;05(02).
39. Martindale WD. *Martindale: the complete drug reference*. 37th ed. Sweetman SC, editor. London: Pharmaceutical Press; 2011.
40. Robottom BJ, Reich SG. Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: Case report and literature review. *Neurologist*. November 2011;17(6):340–1.

41. Dammak M. Treatment-Resistant Schizophrenia: Prevalence and Risk Factors. *Mental Disorders - Theoretical and Empirical Perspectives*. 16 Januari 2013;1–22.
42. Castle DJ, Wessely S, Murray RM. Sex and Schizophrenia: Effects of Diagnostic Stringency, and Associations with Premorbid Variables. *British Journal of Psychiatry*. 1993;162:658–64.
43. Sommer IE, Tiihonen J, van Mourik A, Tanskanen A, Taipale H. The clinical course of schizophrenia in women and men—a nation-wide cohort study. *NPJ Schizophr*. 1 Desember 2020;6(12).
44. Roberts JS, Blow FC, Copeland LA, Barry KL, Stone W van. Age-Group Differences in Treatment Outcomes for Male Veterans with Severe Schizophrenia: A Three-Year Longitudinal Study. *Sage Journals*. Juli 2000;13(2).
45. Winarti AR, Djuwita RH. Prevalence Of Schizophrenia In South Jakarta Administration City In 2017. *Jurnal Ilmu Kesehatan Masyarakat*. 8 April 2019;10(1):15–24.
46. Schneiderman N, Ironson G, Siegel SD. Stress and health: Psychological, behavioral, and biological determinants. *Annu Rev Clin Psychol*. 2005;1:607–28.
47. Venkatesh BK, Thirthalli J, Naveen MN, Kishorekumar K v. Sex difference in age of onset of schizophrenia. *World Psychiatry*. Oktober 2008;7(3):173–6.
48. Immonen J, Jääskeläinen E, Korpela H, Miettunen J. Age at onset and the outcomes of schizophrenia: A systematic review and meta-analysis. *Early Interv Psychiatry*. 1 Desember 2017;11(6):453–60.
49. Häfner H. From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness. *Psychiatry J*. 16 April 2019;2019:1–15.
50. Weinberger DR. Implications of Normal Brain Development for the Pathogenesis of Schizophrenia. *Arch Gen Psychiatry* [Internet]. Juli 1987;44(7):660–9. Tersedia pada: <http://archpsyc.jamanetwork.com/>
51. Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: Perspectives from structural neuroimaging studies. *Schizophr Bull*. Mei 2011;37(3):504–13.
52. Simbolon MJ. Usia Onset Pertama Penderita Skizofrenik Pada Laki Laki dan Perempuan Yang Berobat Ke Badan Layanan Umum Daerah Rumah Sakit Jiwa Propinsi Sumatera Utara. *Artikel Penelitian Majalah Kesehatan Pharmamedika*. 2013;5(1).

53. MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, dkk. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. *Front Psychiatry*. 5 Desember 2018;9.
54. Martínez AL, Brea J, Rico S, de los Frailes MT, Loza MI. Cognitive deficit in schizophrenia: From etiology to novel treatments. *Int J Mol Sci*. 1 September 2021;22(18).
55. Townsend MC. *Psychiatric Mental Health Nursing: Concepts of Care in Evidence-Based Practice*. 8 ed. Philadelphia: F. A. Davis Company; 2020.
56. Widyarti EP, Limantara S, Khatimah H. Gambaran Faktor Prognosis Pada Pasien Skizofrenia Di Rumah Sakit Jiwa Sambang Lihum. *Homeostasis*. Desember 2019;2(3).
57. Erlina E, Soewadi S, Pramono D. Determinan Terhadap Timbulnya Skizofrenia Pada Pasien Rawat Jalan Di Rumah Sakit Jiwa Prof. HB Saanin Padang Sumatera Barat. *Berita Kedokteran Masyarakat*. Juni 2010;26(2).
58. Wayan Darsana I, Luh Putu Suariyani N. Trend Karakteristik Demografi Pasien Skizofrenia Di Rumah Sakit Jiwa Provinsi Bali (2013-2018). *Archive of Community Health*. 2020;
59. Wahyudi A, Fibriana AI. Faktor Resiko Terjadinya Skizofrenia (Studi Kasus di Wilayah Kerja Puskesmas Pati II). *Public Health Perspective Journal [Internet]*. 2016;1(1). Tersedia pada: <http://journal.unnes.ac.id/sju/index.php/phpj>
60. Maramis WF, Maramis AA. *Catatan Ilmu Kedokteran Jiwa*. 2 ed. Surabaya: Airlangga University Press; 2009.
61. Novitayani S. Karakteristik Pasien Skizofrenia Dengan Riwayat Rehospitalisasi. *Idea Nursing Journal*. 2016;7(2).
62. Ganguly P, Soliman A, Moustafa AA. Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment. *Front Public Health*. 7 Juni 2018;6.
63. Dombi ZB, Barabássy Á, Sebe B, Laszlovszky I, Németh G. Clinical Staging in Schizophrenia Spectrum Disorders. Dalam: *Psychosis - Phenomenology, Psychopathology and Pathophysiology [Internet]*. 2021. Tersedia pada: www.intechopen.com
64. Nisa A, Yulita Fitriani V, Ibrahim I. Karakteristik Pasien Dan Pengobatan Penderita Skizofrenia Di RSJD Atma Husada Mahakam Samarinda. *Pharm Chem*. 2014;2(5).

65. Ferdiantoro A, Azizah N, Algristian H. Case Report: Paranoid Schizophrenia with Stressing Point Screening for Paranoid Schizophrenia Prognosis. *International Islamic Medical Journal*. Desember 2021;3(1).
66. Pinkham AE, Harvey PD, Penn DL. Paranoid individuals with schizophrenia show greater social cognitive bias and worse social functioning than non-paranoid individuals with schizophrenia. *Schizophr Res Cogn*. 1 Maret 2016;3:33–8.
67. Hanief N, Noor DN. Gambaran Penggunaan Obat Antipsikotik Pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Periode Januari-Juni 2017. *Yarsi Journal of Pharmacology*. Januari 2021;2(1).
68. Claudia Sendika N, Kartika Untari E. Profil Penggunaan Antipsikotik Tipikal Pada Pasien Skizofrenia di Rumah Sakit Jiwa Daerah Sungai Bangkong Pontianak. *Portal Jurnal Ilmiah Universitas Tanjungpura*. 2019;4(1).
69. American Psychiatric Association. *The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia*. 3rd ed. Washington, DC: Library of Congress Cataloging-in-Publication Data; 2020. 297 hlm.
70. Wang J, Jiang F, Zhang Y, Cotes RO, Yang Y, Liu Z, dkk. Patterns of antipsychotic prescriptions in patients with schizophrenia in China: A national survey. *Asian J Psychiatr*. 1 Agustus 2021;62.
71. Oh S, Lee TY, Kim M, Kim SH, Lee S, Cho S, dkk. Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital. *NPJ Schizophr*. 1 Desember 2020;6(1).
72. Paramitha R, Endang E, Kartika M. Analisis Rasionalitas Penggunaan Antipsikotik Pada Pasien Skizofrenia Di Instalasi Rawat Inap RSJD Atma Husada Mahakam Samarinda Tahun 2016. *Jurnal Farmasi Indonesia [Internet]*. 2018;15(1). Tersedia pada: <http://journals.ums.ac.id/index.php/pharmacon>
73. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 1: Pathophysiology and Mechanisms of Induction. *Can J Psychiatry*. Agustus 2005;50(9):541–7.
74. Desmarais JE, Beauclair L, Annable L, Bélanger MC, Kolivakis TT, Margolese HC. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. *Ther Adv Psychopharmacol*. 2014;4(6):257–67.

75. de Hert M, Wampers M, van Winkel R, Peuskens J. Anticholinergic use in hospitalised schizophrenic patients in Belgium. *Psychiatry Res.* 30 Agustus 2007;152(2-3):165-72.
76. Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. *Psychiatry Clin Neurosci.* Januari 2014;68(1):37-49.
77. Mahal P, Nishanth KN, Mahapatra A, Sarkar S, Balhara YPS. Trihexyphenidyl misuse in delusional disorder. *J Neurosci Rural Pract.* 1 Juli 2018;9(3):428-30.
78. Buhrich N, Weller A, Kevans P. Misuse of Anticholinergic Drugs by People With Serious Mental Illness. *Psychiatr Serv.* Juli 2000;51(7):928-9.

